Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Income towards Parent Company: 2022-2025

Historic Income towards Parent Company for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$8.2 million.

  • InMed Pharmaceuticals' Income towards Parent Company fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.34% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$8.2 million for FY2025, which was down 6.34% from -$7.7 million recorded in FY2024.
  • InMed Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$7.7 million during FY2024, with a 5-year trough of -$18.6 million in FY2022.
  • In the last 3 years, InMed Pharmaceuticals' Income towards Parent Company had a median value of -$7.9 million in 2023 and averaged -$7.9 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Income towards Parent Company soared by 57.27% in 2023, and later dropped by 6.34% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$18.6 million in 2022, then spiked by 57.27% to -$7.9 million in 2023, then rose by 3.42% to -$7.7 million in 2024, then fell by 6.34% to -$8.2 million in 2025.